, we considered the possibility that the tyrosine-like phenolic ring of resveratrol might fit into the active site pocket to effect a nuclear role. Here we present a 2.1 Å co-crystal structure of resveratrol bound to the active site of TyrRS. Resveratrol nullifies the catalytic activity and redirects TyrRS to a nuclear function, stimulating NAD 1 -dependent auto-poly-ADP-ribosylation of poly(ADP-ribose) polymerase 1 (PARP1). Downstream activation of key stress signalling pathways are causally connected to TyrRS-PARP1-NAD 1 collaboration. This collaboration is also demonstrated in the mouse, and is specifically blocked in vivo by a resveratroldisplacing tyrosyl adenylate analogue. In contrast to functionally diverse tRNA synthetase catalytic nulls created by alternative splicing events that ablate active sites 7 , here a non-spliced TyrRS catalytic null reveals a new PARP1-and NAD
1
-dependent dimension to the physiological mechanism of resveratrol.
Human TyrRS is a homodimer of a 528 amino-acid polypeptide that harbours an appended eukaryote-specific carboxy (C)-terminal EMAP-II domain (Fig. 1a ) 8, 9 . High-resolution structures of the catalytic unit of Hs TyrRS, known as mini-TyrRS, and the C-domain have been determined 10, 11 . We found resveratrol (RSV) strongly inhibited TyrRS with an inhibition constant (K i ) value of 22 mM (Extended Data Fig. 1a-c) . Crystallization of Hs mini-TyrRS with RSV and, separately, with tyrosine yielded co-crystal structures (at 2.1 Å ) ( Table 1 ; Protein Data Bank (PDB) accession numbers 4Q93 and 4QBT).
While the phenolic ring of RSV and of the tyrosine have the same disposition in the respective co-crystals, accommodation of the cisconformation of the dihydroxy ring of RSV forces a local structural change near the linker to the C-domain (Fig. 1b and Extended Data Fig. 2a ). An RSV-promoted conformational change in TyrRS may drive the predominant trans RSV (in solution) into a cis conformation (Extended Data Fig. 2c, d ).
Associated with a previous study 12 , a distinct TyrRS-PARP1 interaction was observed. PARP1 is a major modulator of NAD 1 metabolism and its related signalling 13 . Because RSV acts through NAD 1 -dependent proteins 14 , the TyrRS-PARP1 interaction was further studied. Given that RSV treatment elicits a stress response 2 , serum starvation was used to mimic a general 'stand-alone' stress condition so that common signalling pathways, if any, between RSV treatment and a general stress condition, could be compared ex vivo. Either serum starvation or RSV treatment promoted nuclear translocation of endogenous TyrRS in HeLa cells (Fig. 1c) . Translocation was observed under different stress conditions (heat shock and endoplasmic reticulum stress; Extended Data Fig. 3a) , suggesting that TyrRS is a general stress transducer. Nuclear translocation of endogenous TyrRS was concomitant with strong autoPARylation of PARP1 (PARP1 PAR ) ( Fig. 1c and Extended Data Fig. 3a) . Ex vivo RSV also strongly promoted association of TyrRS with PARP1, and robust auto-poly-ADP-ribosylation of PARP1 (Extended Data  Fig. 3b ). Effects of RSV were blocked by a Tyr-AMP analogue (Tyr-SA (59-O-[N-(9L-tyrosyl) sulphamoyl] adenosine)), but not by Gly-SA (a control targeting GlyRS) (Extended Data Fig. 3b, c) . Similar, but less pronounced, PARylation was seen with serum starvation. Enhanced PARylation correlated with increased amounts of TyrRS in the nucleus, which occurred upon serum starvation. Thus, both serum starvation and RSV promoted nuclear translocation of TyrRS and activation of PARP1.
Cell lysates treated with the PARG hydrolyase and its hydrolaseinactive mutant supported the idea that TyrRS preferentially bound to non-PARylated PARP1 (Extended Data Fig. 3d, e) . TyrRS interacted specifically with the C-domain of PARP1 (CT-PARP1) (Extended Data Fig. 3f ). Neither mini-TyrRS nor the TyrRS C-domain interacted with PARP1; only full-length native TyrRS bound PARP1 (Extended Data  Fig. 3g, h ). In the absence of RSV, concentration-dependent activation of PARP1 by TyrRS was observed in vitro (Fig. 2a, top, Data Fig. 4a, b) . RSV enhanced in vitro auto-PARylation with the halfmaximal effect at roughly 10 nM (Fig. 2a, Fig. 4c ). Therefore, TyrRS-RSV activation of PARP1 is distinct. Ectopically expressed TyrRS in HeLa cells for 0-24 h caused progressive increase in cellular concentrations of the synthetase (Fig. 2b, top) and a correlated progressive increase in PARP1 PAR (Fig. 2b, top) . A TyrRS mutant (TyrRS-dNLS), with reduced nuclear localization 6 , reduced activation of PARP1 (Extended Data Fig. 4d ). Effects of RSV ex vivo at various concentrations (Fig. 2b, middle) and of Tyr-SA (Fig. 2b , bottom) mirrored those seen in vitro (Fig. 2a, middle and bottom) .
RSV and L-tyrosine produce different bound conformations of TyrRS, seen locally in the high-resolution structures of the two co-crystals ( Fig. 1b and Extended Data Fig. 2a ). These differences could affect the disposition of the C-domain needed for the interaction of TyrRS with PARP1. This domain is tethered to the mini-TyrRS catalytic unit by a flexible linker (Fig. 2c, left) . By breaking the Y341 OH-H bond to a backbone carbonyl oxygen, a Y341A mutation releases tight tethering of the C-domain to the catalytic domain 15 and its reorientation 16 (Fig. 2c,  right) .
In the absence of RSV, Y341A-TyrRS showed robust interaction with and activation of PARP1 in vitro (Fig. 2d) . If Y341A is shifted more towards a conformation needed to bind to PARP1, then it would be more sensitive than wild-type TyrRS to low concentrations of RSV. This expectation was fulfilled (Extended Data Fig. 4e ). TyrRS-Tyr may thus have a conformation that prevents interaction with PARP1, while TyrRS-RSV has a distinct conformation that binds PARP1. In the absence of either ligand, a dynamic equilibrium populates both forms (Fig. 2c) .
A working model of downstream signalling markers was developed as detailed in Methods (Fig. 3a) . Effects from serum starvation and RSV administration involve cascades through protein acetylation and phosphorylation effects of serum starvation and of RSV, which have not been linked to TyrRS nor activation of PARP1. Under conditions of serum starvation or RSV administration, the response in HeLa cells of PARylated and acetylated proteins, together with the aforementioned cell-signalling proteins, was monitored for up to 1 h. Either RSV or serum-starvation promoted production of AcK-Tip60 and AcK-ATM (Fig. 3b) . In a temporal response from 0 to 8 h, either or both of serum starvation or 1 mM RSV promoted increased levels of whole-cell PARylated 
LETTER RESEARCH
proteins, Hsp72, AcK382-p53, p-AMPK, pSer36-H2B, p21, FOXO3A, 14-3-3, HO-1, NAMPT, SIRT1, and SIRT6 (Fig. 3c, d ). Also, RSV activated acetylation of Tip60 ex vivo in a concentration-dependent manner (Extended Data Fig. 5a ). As expected from previous reports that acetylation of p53 is indispensible for its activation 17 , a transient increase in acetylation of p53 (AcK382) 1 was evident (Fig. 3c, d ), possibly through a transient inhibition of SIRT1 by the nicotinamide 18 being produced. Consistently, at 15 min, an RSV concentration-dependent reduction in total NAD 1 with concomitant production of nicotinamide and ADPribose was observed (Extended Data Fig. 5b, c) . Thus, serum starvation and RSV rapidly increased all monitored proteins in a way that is dependent on having active PARylation. This rapid increase is consistent with work showing rapid upregulation of PARP1 target genes 19, 20 , possibly because of a broader effect of PARP1 on transcription and associated stress signalling 13, 21 . At longer times, and continuing at low concentrations (#10 mM) of RSV, similarity between responses to RSV and serum starvation was ostensibly seen. By 1 h, low concentrations of RSV elevated the NAD 1 levels similar to those of serum-starvation conditions (Extended Data  Fig. 5d ). Responses of key stress-signalling markers in a more extended period of 8-24 h at 5 mM RSV were mostly similar to those of serum starvation (Extended Data Fig. 5e , f). At 5 mM RSV, levels of PARP1 PAR were sustained longer compared with what was observed at 1 mM RSV (compare 2 h and 8 h time points in Fig. 3d with Extended Data Fig. 5f ) and we thus continued further studies at 5 mM RSV.
A short interfering RNA (siRNA) directed against PARP1 (siRNA PARP1 ) effectively abrogated the RSV-stimulated expression of Hsp72, p-AMPK, SIRT1, FOXO3A, SESN2, NAMPT, PUMA, and SIRT6 (Fig. 4a) . Also, 5 mM RSV promoted induction of BRAC1 and p14ARF (whose genes are directly regulated by PARP1 (refs 22, 23) ). Consistently, the RSV-stimulated inductions of BRCA1 and p14ARF were prevented by siRNA PARP1 (Fig. 4a) , further showing involvement of PARP1 in RSV-mediated induction of these proteins.
In Fig. 4a , RSV treatment led to enhanced activation of p53. However, in the absence of RSV, knockdown of PARP1 resulted in a background increase in the products of these p53-regulated genes. Possibly p53 was activated by the knockdown of PARP1, because removal of PARP1 would enhance background levels of DNA damage. Indeed, activation of p53, as seen by enhanced acetylation and phosphorylation of p53, was observed (Fig. 4a) . siRNA TyrRS -knockdown at 5 mM RSV eliminated induction of, and dramatically reduced amounts of, PARylated PARP1, of whole acetylated proteins, and of AcK382-p53, AcK16-H4 (Tip60 activation), p-AMPK, and pSer36-H2B (AMPK activation) (Fig. 4b) . (Separately, RSV (5 mM) addition did not affect the viability of HeLa cells expressing either siRNA TyrRS or siRNA PARP1 (Extended Data Fig. 6 ).) In contrast, siRNA SIRT1 -knockdown did not affect RSV (5 mM)-mediated production of whole acetylated proteins or, among other downstream markers, activation of PARP1 and induction of SIRT6, FOXO3A, NAMPT, AcK16-H4, p-AMPK 24 , and pSer36-H2B (Extended Data Fig. 7) . Collectively, Fig. 4a, b shows that ex vivo TyrRS and PARP1 collaborate to activate RSV-and serum-starvation responses.
Although the RSV-TyrRS-PARP1 axis initially consumes NAD
1
, at low RSV (5 mM), NAD 1 levels are transiently raised after 1 h owing to NAMPT activation (Extended Data Fig. 5d ). At 1 h at low RSV, induction of NAD 1 levels was abolished with either siRNA TyrRS or siRNA PARP1 (Extended Data Fig. 8 ). NAD 1 depletion by NAMPT inhibition abolished RSV-mediated induction of BRCA1, FOXO3A, NAMPT, SESN2 and SIRT6 (Fig. 4c) . These results are consistent with those using inhibitors against PLC-c and the ryanodine receptor 25 , which inhibit PARP1 activation 26 and ADP-ribose-mediated calcium signalling 25, 27 , and which prevented RSV-mediated AMPK activation. Similarly, a PARP1 inhibitor prevented LKB1 activation by RSV 28 . Mice were injected intravenously the through tail vein with 100 ml of 10 mM RSV and, after 30 min, were euthanized. Compared with the PBS intravenous-injected control, PARylated and acetylated proteins, along with AcK16-H4 and pSer36-H2B, were significantly increased in skeletal muscle (Extended Data Fig. 9a, b) . Results in cardiac tissue were similar (Extended Data Fig. 9c, d ). In addition, PARP1 activation diminished back to normal by 24 h (Extended Data Fig. 9e ). Consistent with ex vivo assays, tissue samples from RSV-injected mice showed higher levels of TyrRS-PARP1 interaction together with increased auto-PARylation (Extended Data Fig. 9f) .
Tyr-SA (5 mM) was added to the intravenous-injection with RSV. No interaction of TyrRS with PARP1 could be detected in skeletal or cardiac muscle and levels of PARylated and acetylated proteins did not increase. In contrast, co-injection of Gly-SA or cycloheximide (CHX, protein synthesis inhibitor) did not block RSV/TyrRS-mediated activation of PARP1 and its downstream signals (Fig. 4d (muscle) and Extended Data Fig. 9g, h (cardiac) ). Consistent with ex vivo assays, immunoprecipitation of PARP1 (from harvested muscle tissue) pulled down TyrRS, and immunoprecipitation of p53 showed its increased ; all the samples were run on the same gel. c, NAMPT inhibition abrogates resveratrol-mediated downstream signalling events. HeLa cells were pre-treated with STF-118804 (100 nM), a NAMPT inhibitor, for 16 h and then treated with resveratrol (5 mM), with samples collected at intervals as indicated. Various signalling events, as depicted, were monitored using appropriate antibodies. Acetylation status was monitored using a-acetyl-lysine. The dashed line separates results without and with the inhibitor. d, Resveratrol-mediated activation of PARP1 is blocked by Tyr-SA. Activations of Tip60 and AMPK were monitored by using a-AcK16-H4 and a-pSer36-H2B, respectively. e, Resveratrol-mediated interaction of TyrRS with PARP1 and acetylation of p53 are blocked by Tyr-SA. Immunoprecipitation of PARP1 and p53 from muscle tissue demonstrated RSV-mediated TyrRS-PARP1 interaction and p53 acetylation.
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acetylation. Pull-down of TyrRS and p53 acetylation were blocked in mice that had co-injections of Tyr-SA or the AG14361 (SelleckChem) PARP1 inhibitor, but not of Gly-SA or cycloheximide (Fig. 4e) . These responses in vivo parallel ex vivo assays, and support the idea that TyrRS is a major effector target for RSV that acts through PARP1 as described in Fig. 3a .
The mechanisms of action of RSV and of the stress response are both linked here to the activation of PARP1 through TyrRS and NAD
1
. The interaction of RSV with TyrRS could be viewed as an example of xenohormesis through interactions of a natural ligand with a protein target 29 . In this instance, the natural ligand blocks the active site to create a tRNA synthetase catalytic null with a new, orthogonal function. This kind of catalytic null is in contradistinction to those created by alternative splicing events that specifically remove the active site 7 . The RSV-TyrRS activation of PARP1 is readily observable in a functional in vitro assay even at sub-micromolar concentrations (for example, 10 nM; Fig. 2a, middle) . Thus, TyrRS-RSV-induced PARP1 activation appears at significantly lower RSV concentrations than seen with RSV functional binding to other targets 1, 25, 30 . As a consequence, the direct effects of RSV binding to these targets of RSV are layered over a pre-existing foundation that comes from the TyrRS-RSV-PARP1-NAD 1 connection.
METHODS
Construction of the working model. , and hence an indispensible component for AMPK activation by resveratrol 43 and the stress response by phosphorylating H2B 44 . AMPK is known to upregulate NAMPT expression 45 , the major regulator of NAD 1 levels in the cell 46 . NAD 1 is major substrate for sirtuins (deacetylation or mono-ADP-ribosylation 38, 47, 48 ) and PARPs ((mono/poly)-ADPribosylation 13, 49 ). Although not depicted, p38 and NF-kB (major transducers of stress signalling) are also regulated by TAK1 in a PARP1/ATM-dependent manner 50, 51 . Antibodies. All antibodies were obtained from Cell Signaling Technology unless otherwise mentioned and those as follows: a-ATM was from Abcam and GeneTex; a-PARP1 and a-poly(ADP-ribose) were from BD Biosciences; a-p84 was from Sigma; a-pSer36-H2B from ECM Biosciences; rabbit a-human TyrRS polyclonal antibodies were homemade. a-Tip60 was from Millipore; a-AcK16-H4 was from Active Motif; and a-Hsp72 (catalogue number SPA-812) was from Assay Designs. Cell culture, transfection, and resveratrol treatment. HeLa cells (from ATCC, mycoplasma free) were cultured in a humidified incubator with 5% CO 2 in DMEM medium (Invitrogen) supplemented with 10% FBS (Invitrogen) and 13 penicillin/ streptomycin. The cells were transfected with pcDNA6-TyrRS-V5 (wild type), or pcDNA3.1-ZZ-PARP1 using Lipofectamine LTX (Invitrogen). Resveratrol (SantaCruz Biotechnologies), at a series of concentrations from 0 to 50 mM, was used to treat HeLa cells 0-24 h in experiments described. As the effects of RSV are strongly influenced by the background level of PARP1 activity, the experiments were done only after checking to verify that background PARP1 activation was low. Our criterion was to see PARP1 activation upon serum starvation (DMEM medium without FBS), along with Hsp72 induction 52 . When serum starvation induced PARP1 activation with Hsp72 induction within 30-45 min (from the same batch of a split of HeLa cells), we consistently saw PARP1 activation at lower concentrations of RSV (1 mM). Cell culture medium was supplemented with Tyr-SA or Gly-SA (RNA-TEC) where mentioned. Silencer Select Pre-Designed siRNA against PARP1 (siRNA s1099, 59-GCAGCUUCAUAACCGAAGAtt-39), SIRT1 (siRNA s23770, 59-GGCUUG AUGGUAAUCAGUAtt-39) and TyrRS (siRNA s443, 59-GGACUUUGCUGCU GAGGUUtt-39) were purchased from Invitrogen and transfected into HeLa cells using Lipofectamine RNAiMAX (Invitrogen). NAMPT, the rate-limiting enzyme in the NAD 1 salvage pathway, was inhibited using STF-118804 53 according to the manufacturer's protocol (SelleckChem). The effect of a concomitant increase in nicotinamide production with a reduction of NAD 1 concentration (leading to SIRT1 inhibition) was monitored by immunoblotting with a-AcK382-p53, an acetylation site known to be specifically targeted by SIRT1 (ref. 1). Monitoring of a-pSer 15-p53 indicated if enhanced acetylation preceded the phosphorylation event 54 . Total p53 was blotted with a-p53. Transactivation of p53 was determined by monitoring its known targets, such as p21, PUMA, 14-3-3, FOXO3A, SESN2, and SIRT6. Activation of NRF2 was further confirmed by following HO-1 expression, using the cognate antibodies. Activation of AMPK (Thr 172-phosphorylation) mediated through AMP and Ca 21 influx 25 was monitored using a-pThr 172-AMPK. Activation of AMPK on its targets was further determined by both a-pSer 36-H2B and by the expression level of NAMPT. Cell viability assay. HeLa (1 3 10 6 ) cells were reverse-transfected with siRNAs and viability was monitored using an RTCA iCELLigence System (ACEA Biosciences). HeLa cells were cultured in a humidified incubator with 5% CO 2 in DMEM medium (Invitrogen) supplemented with 10% FBS (Invitrogen) and 13 penicillin/ streptomycin. Preparation of cell fractions. Protocol for cell fractionation was followed as described previously 12 . Briefly, for whole-cell lysate preparation, HeLa cells were dissolved in 13 SDS-polyacrylamide gel electrophoresis (SDS-PAGE) loading buffer containing 300 mM NaCl. For cytoplasmic fraction preparation, HeLa cells were suspended in 0.1 ml of swelling buffer for 6 min on ice, then incubated with 0.1 ml of plasma membrane lysis buffer for 5 min on ice. The cells were immediately passed through a 21-gauge needle ten times and centrifuged for 10 min at 3220g, 4 uC. The supernatant was harvested, while the pellets were used for the preparation of nuclear fractions. For this purpose, the pellet (nuclei) was incubated for 30 min at 4 uC with 0.2 ml nuclear extraction buffer. Whenever required, PARP1 (AG14361) and PARG inhibitors (ADP-HPD, Millipore) were added to the cell lysis buffer to ensure unwanted PARylation and removal of PAR chains with PARG. Immunoprecipitation and Ni-NTA pull-down assays. Protocol for immunoprecipitation was followed as described previously 12 . Briefly, the supernatants were pre-cleared by incubation with protein G beads. The pre-cleared cell lysates were incubated at 4 uC for 1 h with either a-PARP1, a-ATM, a-DNA-PKcs, a-TyrRS, a-Tip60, or non-immune immunoglobulin-G (IgG), at a concentration of 5 mg ml 21 followed by incubation with 30 ml Protein G beads (pretreated with 10 mg ml 21 BSA) at 4 uC for 1 h with rotation. PARP1 (AG14361) and PARG inhibitors (ADP-HPD, Millipore) were added to the cell lysis buffer to ensure unwanted PARylation and removal of PAR chains with PARG. Immunoprecipitates were washed three times, subjected to SDS-PAGE and immunoblotted with specific antibodies. Whenever mentioned, the ZZ domain allowed immunoprecipitation of ectopically expressed ZZ-PARP1, using anti-IgG. Whenever Ni-NTA pull-down was performed, proteins with a 63 -His tag were overexpressed in Escherichia coli. Cells were lysed and the supernatant fractions containing the soluble proteins were mixed with HeLa cell lysates. For Ni-NTA pull-downs, normal procedures for immunoprecipitation were followed with 15-20 mM imidazole in the washing buffer. Animal experiments. All experiments were approved by The Scripps Research Institute Institutional Animal Care and Use Committee (protocol number 13-0002) and conducted by the mice facility at The Scripps Research Institute. BALB/cByJ mice were originally purchased from Jackson Laboratories. Six-week-old male mice were kept with a 12 h light-dark cycle with free access to food and water for 3 days before conducting the experiment. For all studies, mice were dosed once and collected sample after either at 30 min or at 24 h. Briefly, activation of PARP1 in mouse tissues treated with resveratrol was performed by the intravenous injection of a 100 ml sample of resveratrol (10 mM) in PBS into eight mouse tails (0.012 mg kg
21
). A 100 ml PBS injection was used as a control in six mice. Tissue samples were collected from four resveratrol-treated mice and three control mice after 30 min treatment. Tissue samples from the remaining mice were collected after 24 h. In a different experiment, blocking of resveratrol-mediated activation of PARP1 by Tyr-SA was analysed with five groups of two mice each, a 100 ml sample of resveratrol (10 mM) in PBS alone and, separately, with Tyr-SA (5 mM), Gly-SA (5 mM), cycloheximide (5 mM), or the AG14361 PARP1 inhibitor (10 mM) was injected intravenously. A 100 ml PBS injection with Tyr-SA was used in a control group (two mice) as indicated. Tissue samples were collected after 30 min treatment. Muscle or heart tissues samples were homogenized and analysed by immunoblotting for the status of poly-ADP-ribosylation and associated signalling events. Recombinant protein purification. Human TyrRS, PARP1 and their variants were purified as previously described 10, 12 . Briefly, DNA encoding either full-length TyrRS (amino acids 1-528), mini-TyrRS (amino acids 1-341), dN-TyrRS (amino acids 237-528), or CT-TyrRS (amino acids 324-528) was cloned into Nde-I/Hind-III sites of pET-20b vector (Novagen). The expressed proteins included a 6-His tag from the vector sequence. The full-length PARP1 and its variants (amino (N)-and C-terminal domains) were cloned into pET 20b vector. All proteins having a C-terminal His-tag were expressed in E. coli strain BL21 (DE3) by induction for 4 h with 1 mM isopropyl b-D-thiogalactopyranoside. Proteins were purified from the supernatants of lysed cells using Ni-NTA agarose (Qiagen) column chromatography according to the manufacturer's instructions. We also included an additional high-salt two-column wash (1-1.5 M NaCl), to remove the endogenous DNA/RNA associated with the purified protein. The NaCl concentration was increased to 1.5 M in increments and returned to final elution buffer having 250 mM NaCl in decrements. All the proteins were subjected to a gel-filtration (S-200) chromatography and the protein peak corresponding to homogenous protein was collected. As endotoxin associated with purified protein interfered with the inhibitory/activating effect of RSV on TyrRS/PARP1, the complete protein purification included an additional endotoxin removal step. The purified protein was further passed through a column containing Detoxi-Gel TM (Pierce-Thermo Scientific) and followed the manufacturer's instructions. The final endotoxin level (0.5 EU mg 21 ml
) was measured using an Endosafe R -PTS kit (Charles River Laboratories). The quality of each protein purification was validated by SDS-PAGE analysis. Protein crystallization and data collection. All the steps were followed as mentioned in the previous report for mini-TyrRS crystallization 10 . Briefly, mini-TyrRS was mixed with either 1 mM RSV or 2 mM tyrosine and incubated at 4 uC for 16 h. Before setting up the crystallization trials, the protein samples were subjected to high-speed centrifugation (15,871 relative centrifugal force for 15 min) to remove all the precipitants and the clear soluble fraction transferred to a new tube. The crystallization trials were done using 2.1 M (NH 4 ) 2 SO 4 , 0.1 M NaH 2 PO 4 /K 2 HPO 4 (pH 6-8), and 2% acetone at room temperature (22-25 uC) . Although, mini-TyrRS crystals with L-tyrosine were grown in 3 days (data collected at Stanford Synchrotron Radiation Lightsource), crystals with RSV were grown only after 3-4 months at around pH 7. X-ray data were collected at 2.1 A using the in-house X-ray diffraction facility (The Scripps Research Institute). Data were integrated and scaled using ) was used as a control. Viability was monitored using the RTCA iCELLigence System (ACEA Biosciences). Samples were treated with RSV (5 mM) at 60 h and monitoring was continued for another 2 h for siRNA TyrRS (a total of 62 h of monitoring) and for another 16 h for siRNA Con and siRNA PARP1 (total 76 h monitoring).
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